about
KIR-HLA genotypes in HIV-infected patients lacking immunological recovery despite effective antiretroviral therapyCD4+ T cell depletion, immune activation and increased production of regulatory T cells in the thymus of HIV-infected individualsHigh-density lipoprotein-cholesterol levels and risk of cancer in HIV-infected subjects: Data from the ICONA Foundation Cohort.Fully immunocompetent CD8+ T lymphocytes are present in autologous haematopoietic stem cell transplantation recipients despite an ineffectual T-helper responseQualitative immune modulation by interleukin-2 (IL-2) adjuvant therapy in immunological non responder HIV-infected patients.Safety and tolerability of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil fumarate in a real life setting: Data from surveillance cohort long-term toxicity antiretrovirals/antivirals (SCOLTA) project.PCR-hybridization assay for Mycobacterium avium complex: optimization of detection in peripheral blood from humansMolecular epidemiology study of exogenous reinfection in an area with a low incidence of tuberculosisUnder representation of the inhibitory KIR3DL1 molecule and the KIR3DL1+/BW4+ complex in HIV exposed seronegative individuals.Prospective immune dynamics during the first 24 weeks of efavirenz based-antiretroviral therapy in HIV-1-infected subjects, according to CD4+ T-cell counts at presentation: the IMMUNEF clinical trialFocal bone lesions in HIV-positive patient treated with tenofovirSpecific prebiotics modulate gut microbiota and immune activation in HAART-naive HIV-infected adults: results of the "COPA" pilot randomized trialA case of classic neuromyelitis optica (Devic's syndrome) triggered by pegylated-interferon αEvaluation of the Prognostic Value of Impaired Renal Function on Clinical Progression in a Large Cohort of HIV-Infected People Seen for Care in Italy.Neurocognitive impairment in HIV-infected naïve patients with advanced disease: the role of virus and intrathecal immune activation.Spoligotyping and Mycobacterium tuberculosisThe prognostic role of systemic inflammatory markers on HIV-infected patients with non-Hodgkin lymphoma, a multicenter cohort study.Systemic inflammation-based scores and mortality for all causes in HIV-infected patients: a MASTER cohort studyUnmasking tuberculosis in the era of antiretroviral treatment.3-Year efficacy and durability of simplification to single tablet regimens: a comparison between co-formulated efavirenz/emtricitabine/tenofovir and rilpivirine/emtricitabine/tenofovir.A case of costochondral abscess due to Corynebacterium minutissimum in an HIV-infected patient.Analysis of the env V3 sequences obtained from patients with HIV type 1 infection treated with the immune modulant agent tucaresol.Strategies to limit immune-activation in HIV patients.Nosocomial bacterial pneumonia in HIV-infected patients: risk factors for adverse outcome and implications for rational empiric antibiotic therapy.Comparison between spoligotyping and IS6110 restriction fragment length polymorphisms in molecular genotyping analysis of Mycobacterium tuberculosis strains.Interleukin-2 immunotherapy exerts a differential effect on CD4 and CD8 T cell dynamics.Low-dose prolonged intermittent interleukin-2 adjuvant therapy: results of a randomized trial among human immunodeficiency virus-positive patients with advanced immune impairment.Systemic Inflammation-Based Biomarkers and Survival in HIV-Positive Subject With Solid Cancer in an Italian Multicenter Study.wHospital: a web-based application with digital signature for drugs dispensing management.Genotyping analyses of tuberculosis transmission among immigrant residents in Italy.Brief Report: Peripheral Monocyte/Macrophage Phenotypes Associated With the Evolution of Cognitive Performance in HIV-Infected Patients.Drop in CD4+ counts below 200 cells/µL after reaching (or starting from) values higher than 350 cells/µL in HIV-infected patients with virological suppression.Occupational HIV Infection in a Research Laboratory With Unknown Mode of Transmission: A Case Report.Triglyceride/HDL ratio and its impact on the risk of diabetes mellitus development during ART.Brachial and central blood pressure in HIV-infected subjects.Exogenous reinfection of tuberculosis in a low-burden area.Early consolidation with high-dose therapy and autologous stem cell transplantation is a feasible and effective treatment option in HIV-associated non-Hodgkin lymphoma at high risk.Changes in subcutaneous adipose tissue microRNA expression in HIV-infected patients.ECMO: an alternative support for acute respiratory failure caused by tuberculosis?Metabolic syndrome in human immunodeficiency virus-positive subjects: prevalence, phenotype, and related alterations in arterial structure and function.
P50
Q28477797-865C985B-8E8C-4B62-9B70-C993DB50B78AQ28751971-4B3A8CF5-331C-4937-8557-1863BD4710F3Q28751971-54F7454F-96A1-4A70-9403-38956D76A58FQ31127155-8F80E429-82D7-4936-AA50-8637FF014C10Q33381644-A980149A-B4D5-4B2E-9A73-073361D66392Q33381644-B9688E25-8918-4CB9-9CE3-7900C213F4D9Q33760657-C7D9B74A-E2A0-4AC0-98E7-7692C3598228Q33817410-A016B5D8-DC48-46DF-BE5B-651F8C397927Q33972068-164E65EE-50AC-4602-8D81-77B9147F5928Q33972068-D90F73E4-1EE2-4FDB-84B5-5B38894A166EQ33972593-747676D8-65D7-4C66-9A75-AE2C85C7DFA2Q33972593-EB51974E-542C-4554-9685-0B79F5EA799FQ34754902-7F582CD6-4765-4369-B131-9831E8C22372Q34754902-D4083CB4-81FE-485D-9CCE-62BAB6137F93Q35074381-1DF5FC22-3236-4970-A6D9-0B02F0F6BC1CQ35074381-71332DF4-DABD-45DF-BC5F-68C5248E1999Q35112499-8DF16E3B-0B0B-4D7C-9D79-09601FC2E6B2Q35112499-F8AA97D3-D31E-4DA4-829C-9BDFD03A8B18Q35171253-3DFA0C28-C63E-4C57-9E5B-4F63AF6459B6Q35171253-61C8FBA9-BD3F-4B3C-AA29-99B9E6579FD9Q35290680-5F50D16C-0D72-4B76-9EC5-DDE24C546FA5Q35290680-75D13E45-F509-4AF1-95FC-9E4D24E2FF95Q35560802-21266FFB-6E7A-4FF3-A1A3-A9F4F554BAF3Q35872249-D1A4AE6D-F8C1-4EAB-ADC9-F90F44A7C1D4Q35872249-FA7F4B49-FDF7-4E83-A211-DECA7E71FBD8Q35873404-4E8DB041-CA89-405F-B6A5-345DA4D20E02Q36034748-16FC4B92-FDEF-4977-B22D-3BB7DE07AE91Q36034748-7580A617-569B-46BF-B9C4-50C6893F5AADQ36298753-50481D03-E892-4D8C-AE96-E8ACF3883687Q37946719-BD338B09-F1FF-4BF1-892F-4291E2B3F78DQ38629060-4037EFBB-8D7E-4404-BB2F-D7243FB2CFBFQ38890909-D68A6C1D-1DD3-47E6-91A9-8A49D429DB91Q38890909-E8C693BD-6DAC-4D7E-8878-F9116B607BCEQ38925437-4C983E0B-101C-4FC5-8749-511411FFCEB8Q38925437-F306B325-886B-49D2-9142-62945CE55503Q38985926-D2966976-4419-4228-9646-9213DF035154Q39010901-BF0B0499-A164-457B-9901-9D0B5B793DEBQ39010901-DE3C2DF5-9A10-4DAF-AC21-1052E5F8759AQ39029343-8D9F90FC-0BD7-4883-BC79-2056684F2901Q39214144-2E01DC96-6F8D-439A-B1D9-25E6314A4E36
P50
description
hulumtuese
@sq
researcher
@en
ricercatrice
@it
wetenschapper
@nl
հետազոտող
@hy
name
Alessandra Bandera
@ast
Alessandra Bandera
@en
Alessandra Bandera
@es
Alessandra Bandera
@nl
type
label
Alessandra Bandera
@ast
Alessandra Bandera
@en
Alessandra Bandera
@es
Alessandra Bandera
@nl
prefLabel
Alessandra Bandera
@ast
Alessandra Bandera
@en
Alessandra Bandera
@es
Alessandra Bandera
@nl
P214
P106
P1153
7004558845
P21
P214
P31
P396
IT\ICCU\CFIV\253674
P496
0000-0001-9440-4601
P5008
P735
P7859
viaf-307337258